Abstract
M. agalactiae (Mycoplasma agalactiae) is the main agent of CA (contagious agalactia) that is primarily disease of dairy sheep and goats. In Iran, a three-valent Agalactia inactivated vaccine were prepared based on three M. agalactiae isolated from milk secretion of sheep and goat of Taleghan, Shiraz and Lorestan and preventive policies against CA disease founded in Razi Institute since 1966. The P30 is a specific and stable lipoprotein of M. agalactiae. In this study, complete coding sequence of P30 gene of three Iranian vaccine strains and ten recently field isolates were analyzed in nucleotide and protein levels by bioinformatics tools. Interestingly, results observed a novel protein pattern K106VLKTKEIRLSQERKLS122 in P30 protein of vaccine strains compared to field isolates and the other available sequences in GenBank. Our findings demonstrated different B and T cell epitope patterns in Iranian vaccine strains. We suggested that the major change in P30 protein pattern may be occurred due to mutation during adaptation process in PPLO (Pleuropneumonia-Like Organisms) broth media.
Highlights
Contagious agalactia (CA) is primarily a disease of dairy sheep and goats characterized by mastitis, arthritis and keratoconjunctivitis (Amores et al, 2010, Nicolas et al, 2008, Stear, 2005)
Ten field isolates of M. agalactiae which were isolated from 5 provinces of Iran and three vaccine strains were proved by culture and PCR methods
The complete coding sequence of P30 gene with 800bp length was amplified in all field isolates andthree Iranian vaccine strains of M. agalactiaesuccessfully
Summary
Contagious agalactia (CA) is primarily a disease of dairy sheep and goats characterized by mastitis, arthritis and keratoconjunctivitis (Amores et al, 2010, Nicolas et al, 2008, Stear, 2005). This syndrome is produced by Mycoplasma agalactiaeand causes the reduction and the suppression of milk production and death in many young animals (Katarína et al, 2009, Madanat et al, 2001, Tola et al, 1997). Prevention and eradication of CA can be obtained through better diagnostic tests and through a more efficient vaccine (Greco et al, 2002)
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
